The video provides a fundamental analysis of HIMS stock, downgrading its rating from 'buy' to 'hold'. On August 5, 2025, HIMS was rated as a 'buy' when its stock was trading at a lower valuation. The stock is up almost 30% in the last month. HIMS experienced revenue growth, from $0.1 billion in 2020 to $2 billion in 2025. The company's operating profit margin has improved from -39% in 2021 to 6.5% in 2025. It is now trading at a forward P/E of 79.41. The analyst's intrinsic value per share is $45.81. Considering the current market price and the risk compared to the weight loss treatment, a hold rating is recommended.